Le Lézard
Classified in: Health, Science and technology, Business
Subject: LIC

Emendo Biotherapeutics Enters Into Licensing Option Agreement With Takeda for its OMNI Nuclease Program


NEW YORK, April 24, 2019 /PRNewswire/ -- Emendo Biotherapeutics Inc today announced that the company signed a licensing option agreement with Takeda Pharmaceutical Company Limited. As part of the transaction, Emendo will receive an investment in convertible notes from Takeda Ventures, Inc., the corporate venture arm of Takeda. The funds will be used to further advance Emendo's novel nuclease gene editing discovery platform and proprietary product development programs.

The licensing option agreement grants Takeda the option to use OMNI, Emendo's proprietary nuclease program, to edit two genes as part of its research and development efforts. Further, Emendo will apply its novel gene editing engineering platform to optimize the OMNI nuclease to have the highest specificity and activity on Takeda's chosen genes.

"Extending our investment in Emendo and licensing its nuclease discovery platform and gene editing technology is another example of Takeda's commitment to investing in transformative advances in science via mutally advantageous partnerships," said Takeda Ventures Senior Partner Rob Woodman.

The notes will be converted in Emendo's planned B round financing intended to allow the company to advance its high precision gene editing biotherapies into initial clinical trials.  Emendo is moving several preclinical programs through optimization, in preparation for moving towards the clinic in a number of promising clinical indications. 

Emendo's gene editing program, OMNI, enables extremely specific gene editing which minimizes off target cuts and allows for highly focused therapeutic intervention in complex genetic diseases. 

Emendo's CEO, David Baram, says "We're pleased to be working with an innovative global pharmaceutical leader such as Takeda. This agreement further positions Emendo as a leading, next-generation, high-precision, gene editing company and promotes its allele specific editing programs that can potentially cure severe genetic disorders."

About Emendo

Emendo is a genome editing company developing genetic medicines and cell therapies for severe diseases. Emendo's cutting-edge technology is based on its proprietary protein engineering and selection platforms, designed to generate ultra-specific and highly active CRISPR OMNI nucleases, carefully optimized per target sequence for generating safe and effective genetic solution. Emendo was established in 2015 with investments by OrbiMed Advisors LLP And Takeda Ventures, Inc. the corporate venture arm of Takeda Pharmaceuticals Limited.

For more information:

David Baram, CEO
David@emendobio.com
+972-54-4907749


These press releases may also interest you

at 18:10
Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, today announced that an abstract describing clinical data regarding their lysine-specific demethylase (LSD1)...

at 18:08
This report provides forecast and analysis of the global medical nutrition market.It provides estimated data of 2018, and forecast data up to 2027 in terms of revenue (US$ Mn) and volume (metric tons).Read the full report:...

at 18:08
About this marketThe increasing number of cervical cancer endoscopic device launches is one of the key factors that will trigger the market growth during the forecast period. With the rising prevalence of cervical cancer, manufacturers are focusing...

at 18:08
Global Negative-pressure Wound Therapy Devices Market: OverviewThe global negative-pressure wound therapy devices market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of...

at 18:00
The 17th annual FedEx/St. Jude Angels and Stars Gala benefiting St. Jude Children's Research Hospital® united philanthropists, influencers and celebrities who raised $800,000 for the fight to end childhood cancer on Saturday, May 18, at the...

at 18:00
The "Oman Fitness Services Market Outlook to 2022 - By Gym Membership and Personal Training, by Region, by Gender and by Membership Subscription" report has been added to ResearchAndMarkets.com's offering. Oman fitness services market has witnessed a...



News published on 24 april 2019 at 04:00 and distributed by: